GeoVax is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS. Designed for predominant HIV virus subtypes in the developed world, our most advanced vaccine candidate is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus.

Employee Rating

5.0More
TypePublic
HQSmyrna, US
Founded2001
Size (employees)5 (est)
Websitegeovax.com
GeoVax was founded in 2001 and is headquartered in Smyrna, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at GeoVax

Robert T. McNally

Robert T. McNally

President & CEO
Mark W. Reynolds

Mark W. Reynolds

CFO
Harriet L. Robinson

Harriet L. Robinson

CSO
Show more

GeoVax Office Locations

GeoVax has an office in Smyrna
Smyrna, US (HQ)
1900 Lake Park Dr SE
Show all (1)
Report incorrect company information

GeoVax Financials and Metrics

GeoVax Revenue

USD

Net income (Q3, 2018)

(666.9k)

EBIT (Q3, 2018)

(667.3k)

Market capitalization (8-Oct-2018)

4.1m

Cash (30-Sep-2018)

511.2k

EV

3.6m
GeoVax's current market capitalization is $4.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

1.8m1.8m1.4m2.1m1.2m

R&D expense

2.9m1.8m1.7m2.0m2.0m

Operating expense total

4.7m3.6m3.1m4.1m3.2m

EBIT

(2.3m)(2.7m)(2.7m)(3.3m)(2.2m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

316.5k371.8k344.9k411.8k401.4k364.9k335.9k906.5k344.8k220.7k292.7k352.2k357.2k359.2k459.0k

R&D expense

879.1k402.9k516.2k425.5k403.6k384.7k378.5k438.0k397.6k683.9k551.8k518.1k487.0k372.2k557.7k

Operating expense total

1.2m774.7k861.1k837.3k805.1k749.5k714.5k1.3m742.4k904.6k844.5k870.3k844.2k731.4k1.0m

EBIT

(191.3k)(617.3k)(680.6k)(515.2k)(701.6k)(678.1k)(621.3k)(1.3m)(576.1k)(464.5k)(548.7k)(518.2k)(622.9k)(638.1k)(667.3k)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.5m1.1m1.1m454.0k312.7k

Inventories

43.6k44.5k56.6k62.3k

Current Assets

2.7m1.2m1.2m544.4k448.1k

PP&E

120.2k96.7k83.6k54.8k31.2k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

1.7m2.0m1.4m862.2k3.1m2.5m1.8m669.5k215.1k511.1k166.7k822.6k571.2k191.0k511.2k

Current Assets

1.8m2.0m1.4m926.4k3.2m2.6m1.9m709.0k258.8k602.2k240.4k933.6k802.3k339.1k596.2k

PP&E

106.4k103.6k113.2k105.3k98.1k90.8k76.4k69.2k62.0k52.3k45.4k26.2k21.2k16.3k

Total Assets

2.0m2.2m1.5m1.1m3.4m2.7m2.0m796.5k339.1k675.2k303.7k990.0k839.5k371.4k623.5k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(2.3m)(2.7m)(2.7m)(3.3m)(2.2m)

Depreciation and Amortization

78.9k69.0k28.9k28.8k28.0k

Inventories

(1.3k)(934.0)(12.1k)(5.6k)

Accounts Payable

(14.7k)(125.3k)(60.0k)242.9k441.4k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(1.4m)(615.9k)(1.3m)(1.8m)(700.5k)(1.4m)(619.9k)(1.3m)(1.9m)(464.2k)(548.3k)(1.1m)(621.8k)(1.3m)(1.9m)

Depreciation and Amortization

52.7k16.4k32.7k50.0k14.5k7.2k14.4k13.8k5.0k9.9k14.9k

Accounts Payable

(101.5k)(77.0k)(74.9k)(142.1k)45.9k(5.9k)42.5k39.5k53.2k33.5k150.9k281.7k107.1k252.8k486.4k

Cash From Operating Activities

(872.0k)(503.5k)(1.1m)(1.6m)(1.3m)(629.1k)(1.2m)(761.2k)(381.6k)(761.8k)(1.0m)
USDY, 2018

EV/EBIT

-5.4 x

EV/CFO

-3.5 x

Financial Leverage

-0.9 x
Show all financial metrics
Report incorrect company information

GeoVax Online and Social Media Presence

Embed Graph
Report incorrect company information

GeoVax News and Updates

GeoVax Observes 2018 World AIDS Day

Recognizing the Importance of Partnerships Atlanta, GA - (NewMediaWire) - December 03, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today noted its observance of World AIDS Day 2018. World AIDS Day is a global initiative to raise awareness, fight preju…

GeoVax Provides Update on HIV Clinical Trials Program

Innovative Combination Vaccine Advancing in Clinical Trials 

GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program

Combined Technologies May Yield Therapies for Multiple Cancer Indications  

GeoVax and Virometix to Collaborate on Immunotherapy Program for HPV Infections and Related Cancers

GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology

GeoVax Reports 2018 Third Quarter Financial Results and Provides Corporate Update

Atlanta, GA - (NewMediaWire) - November 08, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel viral vector platform technology, announced its financial results for the quarter ended September 30, 2018, and provided an update on its research an…

GeoVax Presenting at Upcoming Scientific Conferences

Plug & Play Platform Continues to be Recognized for Distinct Benefits
Show more
Report incorrect company information

GeoVax Company Life and Culture

Report incorrect company information

GeoVax Frequently Asked Questions

  • When was GeoVax founded?

    GeoVax was founded in 2001.

  • Who are GeoVax key executives?

    GeoVax's key executives are Robert T. McNally, Mark W. Reynolds and Harriet L. Robinson.

  • How many employees does GeoVax have?

    GeoVax has 5 employees.

  • Who are GeoVax competitors?

    Competitors of GeoVax include MyoKardia, Athersys and Ironwood Pharmaceuticals.

  • Where is GeoVax headquarters?

    GeoVax headquarters is located at 1900 Lake Park Dr SE, Smyrna.

  • Where are GeoVax offices?

    GeoVax has an office in Smyrna.

  • How many offices does GeoVax have?

    GeoVax has 1 office.